Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Julie Zaetta

Diagnostic Radiology Tucson, AZ Medical Doctor

NPI 1710958913 CMS profile 123681

677 N Wilmot Rd, Tucson, AZ 85711

Open in the dashboard

General payments

$5,870

189 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julie Zaetta of Tucson, AZ is reported in the CMS Open Payments database as having received $5,870 across 189 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $830 15
2024 General $969 38
2023 General $1,029 37
2022 General $1,349 39
2021 General $453 20
2020 General $239 18
2019 General $1,000 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julie Zaetta
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Julie Zaetta were reported at $830. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Julie Zaetta Diagnostic Radiology median Middle half National median
2019 $1,000 $108 $29–$318 $163
2020 $239 $65 $21–$252 $114
2021 $453 $92 $24–$292 $132
2022 $1,349 $104 $29–$294 $149
2023 $1,029 $110 $29–$337 $160
2024 $969 $113 $30–$356 $164
2025 $830 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sirtex Medical Inc $1,583 39 payments
  2. Edwards Lifesciences Corporation $896 41 payments
  3. Surefire Medical, Inc. $597 18 payments
  4. Siemens Medical Solutions USA, Inc. $455 3 payments
  5. Amgen Inc. $315 20 payments
  6. Penumbra, Inc. $308 8 payments
  7. Medtronic, Inc. $154 2 payments
  8. Merck Sharp & Dohme Corporation $145 8 payments
  9. Incyte Corporation $142 7 payments
  10. Argon Medical Devices, Inc. $117 1 payment
  11. Other $1,158 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,870 189 payments
Products named General payments · program years 2019–2025
  1. SIR-Spheres Microspheres $1,544 35 payments
  2. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $643 30 payments
  3. TRINAV INFUSION SYSTEM $597 18 payments
  4. Embozene $316 2 payments
  5. SAPIEN 3 Ultra RESILIA $253 11 payments
  6. RUBY Coil $190 5 payments
  7. Varian CRYOCARE TOUCH System $160 1 payment
  8. Cryocare CS $155 1 payment
  9. VISUAL-ICE $145 2 payments
  10. KEYTRUDA $145 8 payments
  11. Other $2,272 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 189 billing codes

Paid by Medicare

$274,648

Of which drugs: $2,117

Medicare patients

2,354

Average age 76

Services billed

25,237

1,265 women, 1,089 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 38%
Chronic kidney disease 32%
Diabetes 29%
Atrial fibrillation 28%
Depression 27%
COPD 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 116 11,850 $1,202
Injection, gadoterate meglumine, 0.1 ml A9575 Office 54 9,750 $898

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JAKAFI
  • Incyte Corporation $28
$28 — —
PEMAZYRE
  • Incyte Corporation $26
$26 — —
Doptelet
  • Sobi, Inc $25
$25 — —
ALUNBRIG
  • Takeda Pharmaceuticals U.S.A., Inc. $21
$21 — —
TUKYSA
  • PFIZER INC. $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record